Patiromer Calcium

CHEMBL2107840 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A calcium-containing form of patiromer, a non-absorbed potassium binder used to treat hyperkalemia (high blood potassium) in adults, particularly those with chronic kidney disease or heart failure taking medications that raise potassium. It exchanges calcium for potassium in the colon, reducing potassium absorption.

Терапевтические области

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A calcium-containing form of patiromer, a non-absorbed potassium binder used to treat hyperkalemia (high blood potassium) in adults, particularly those with chronic kidney disease or heart failure taking medications that raise potassium. It exchanges calcium for potassium in the colon, reducing potassium absorption.

Yes, Patiromer Calcium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107840. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.